

1 FW

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Substitute) PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	Attorney Docket Number	11026/20072															
<table border="1"> <tr> <td colspan="2">Application Number</td> <td>10/635,807</td> </tr> <tr> <td colspan="2">Filing Date</td> <td>August 5, 2003</td> </tr> <tr> <td colspan="2">First Named Inventor</td> <td>RUBENSTEIN, E.</td> </tr> <tr> <td colspan="2">Art Unit</td> <td>3762</td> </tr> <tr> <td colspan="2">Examiner Name</td> <td>Patricia M. Bianco</td> </tr> </table>			Application Number		10/635,807	Filing Date		August 5, 2003	First Named Inventor		RUBENSTEIN, E.	Art Unit		3762	Examiner Name		Patricia M. Bianco
Application Number		10/635,807															
Filing Date		August 5, 2003															
First Named Inventor		RUBENSTEIN, E.															
Art Unit		3762															
Examiner Name		Patricia M. Bianco															

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Statement Under 37 CFR 3.73(b)
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> Postcard - Return Receipt
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

Please charge Attorney Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., Customer No. 03000		
Signature			
Printed name	Eric S. Marzluf		
Date	January 4, 2006	Reg. No.	27,454

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Eric S. Marzluf	Date	January 4, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT
Customer No. 03000
Attorney Docket No. I1026/20072

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION

Applicant(s): RUBENSTEIN, E., et al.

Group Art Unit: 3762

Serial No.: 10/635,807

Filing Date: August 5, 2003

Examiner: Patricia M. Bianco

Confirmation No.: 9762

For: INTERNALLY POWERED CSF PUMP SYSTEMS AND METHODS

REVOCATION OF POWER OF ATTORNEY
AND APPOINTMENT OF NEW POWER OF ATTORNEY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Integra LifeSciences Corporation, the Assignee of the entire right, title and interest in the above-identified patent as specified in the accompanying Statement Under 37 CFR 3.73(b), hereby revokes all prior powers of attorney and appoints the attorneys at United States Patent and Trademark Office **Customer No. 03000** as attorneys of record with full power of substitution and revocation to prosecute the patent and all continuations and divisions thereof, and to transact all business in the Patent and Trademark Office, including the payment of maintenance fees for patent(s) issuing on the application and its progeny.

Please change the correspondence address for the above-identified patent to **Customer No. 03000** (Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., 1635 Market Street, 11th Floor – Seven Penn Center, Philadelphia, PA 19103-2212).


The telephone number of Customer No. 03000 is (215) 567-2010 and the fax number is (215) 751-1142.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

INTEGRA LIFESCIENCES CORPORATION

Date: 12/20/05

By


John B. Henneman III, Executive Vice President



PATENT
Customer No. 03000
Attorney Docket No. I1026/20072

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION

Applicant(s): RUBENSTEIN, E., et al.

Group Art Unit: 3762

Serial No.: 10/635,807

Filing Date: August 5, 2003

Examiner: Patricia M. Bianco

Confirmation No.: 9762

For: INTERNALLY POWERED CSF PUMP SYSTEMS AND METHODS

STATEMENT UNDER 37 CFR 3.73(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Assignee of the entire right, title and interest hereby seeks to take action in the Patent and Trademark Office in this matter.

IDENTIFICATION OF ASSIGNEE

Integra LifeSciences Corporation
(A Delaware Corporation)
311-C Enterprise Drive
Plainsboro, NJ 08436

PERSON AUTHORIZED TO SIGN

I, John B. Henneman III, represent that I am the Executive Vice President of Integra LifeSciences Corporation, and aver that I am empowered to sign this statement on behalf of the Assignee.

BASIS OF ASSIGNEE'S INTEREST

All right, title and interest in and to Application Serial No. 10/635,807 were transferred from the current assignee from the inventor as shown in the chain of title below and as recorded with the Patent and Trademark Office.

1. From: Edward Rubenstein (Filed with Appln. 08/05/2003)
David L. Karshmer
Elliott C. Levinthal
Jaime S. Vargas
Tom A. Saul
To: Eunoe, Inc.
Recorded:
Reel/Frame:


2. From: Eunoe, Inc.
To: Integra LifeSciences Corporation
Recorded: 10/12/2005
Reel/Frame: 016636/0253

DECLARATIONS

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of any patent issuing thereon.

INTEGRA LIFESCIENCES CORPORATION

Date: 12/20/05

By 
John B. Henneman III, Executive Vice President